Gestalt Diagnostics and Deep Bio announced a strategic relationship to develop an integrated workflow for pathologists to use AI algorithms directly within Gestalt’s PathFlow platform to diagnose prostate cancer.
Read More
FoundationOne Liquid CDx Identifies Patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer (mCRPC) who may be appropriate for treatment with Lynparza.
Read More
Mir Scientific is a Fierce Innovation Awards finalist for its liquid biopsy urine test that can accurately detect and grade prostate cancer noninvasively.
Read More
Prolaris is a genetic test that offers an accurate assessment of how aggressively prostate cancer will progress over the next 10 years.
Read MoreTrial results confirm the potential benefits of using biomarkers to guide care for men with metastatic castration-resistant prostate cancer.
Read More